Psychedelic Therapeutics Clinical Trials Research Report 2024 Featuring Yale University, Johnson & Johnson, Shire Pharmaceuticals, Pfizer, Lykos, and UCB
13. September 2024 06:55 ET
|
Research and Markets
Dublin, Sept. 13, 2024 (GLOBE NEWSWIRE) -- The "Clinical Trials: Psychedelic Therapeutics" report has been added to ResearchAndMarkets.com's offering.This report provides a review of global...
Novotech Announces MOU with Experienced Psychedelics Research Center at the 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston
22. Mai 2024 20:11 ET
|
Novotech
Novotech Announces MOU with Experienced Psychedelics Research Center at the 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston
PsychedelicNewsWire Named Official Media Sponsor of the 4th Annual Psychedelic Therapeutics and Drug Development Conference
17. Mai 2024 09:35 ET
|
InvestorBrandNetwork (IBN)
LOS ANGELES, May 17, 2024 (GLOBE NEWSWIRE) -- PsychedelicNewsWire (“PNW”), a specialized communications platform for the psychedelics sector and one of the 60+ brands powered by IBN...
4th Annual Psychedelic Therapeutics and Drug Development Conference Scheduled for May 23-24 in Boston, MA
16. Mai 2024 09:35 ET
|
Arrowhead SciTech Conferences & Events
NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- via PsychedelicNewsWire (“PNW”) — Following three impactful conferences, Arrowhead Sci-Tech Conferences and Events (“Arrowhead”) is pleased to announce the...
Mydecine Provides Q4 2023 Business Update
26. Oktober 2023 02:00 ET
|
Mydecine Innovations Group Inc.
Mydecine is pleased to address its shareholders and provide a general update on the company's progress.
Psychedelic Therapeutics Market Grow at a CAGR 14.92 % from 2023 to 2031 | Exclusive InsightAce Report
27. Juni 2023 10:20 ET
|
InsightAce Analytic Pvt. LTd.
Jersey City, NJ, June 27, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Psychedelic Therapeutics Market Size, Share &...
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leads Out in Psychedelic-Based Therapeutics Space
07. März 2022 08:30 ET
|
Cybin Inc.
NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) announces the availability of a broadcast titled, “Psychedelic Therapies Offer Hope for...
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Unleashing Power of Psychedelics
03. März 2022 08:30 ET
|
Cybin Inc.
NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- via InvestorWire — Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one...
Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease
27. Oktober 2021 08:15 ET
|
SILO PHARMA INC.
Englewood Cliffs, NJ, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Cybin Inc. (NEO: CYBN) at Forefront of Psychedelic Revolution
26. März 2021 08:30 ET
|
Cybin Inc.
NEW YORK, March 26, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Cybin Inc. (NEO: CYBN) announces the availability of a broadcast titled, “Science Drives Surging Interest in Psychedelic...